Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.58 |
| ▸ | NPC1 | O15118 | 2/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | MTOR | P42345 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | HTT | P42858 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.47 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.47 |
| ▸ | TPSAB1 | Q15661 | 2/20 | 0.47 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.44 |
| ▸ | CDK4 | P11802 | 1/20 | 0.43 |
| ▸ | TSPO | P30536 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1690816 | 0.84 | NPC1 (0.82) | RAB9ANPC1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL19002580 | 0.81 | ALDH1A1 (0.69) | RAB9ANPC1KMT2AALDH1A1HTT | |
| SCHEMBL11172546 | 0.81 | RAB9A (0.56) | RAB9ANPC1KMT2AALDH1A1HTT | |
| SCHEMBL19002498 | 0.80 | NSD2 (0.56) | RAB9ANPC1KMT2AALDH1A1HTT | |
| SCHEMBL13869716 | 0.80 | KMT2A (0.84) | RAB9ANPC1KMT2AMTORALDH1A1 | |
| SCHEMBL18868377 | 0.80 | RAB9A (0.51) | RAB9ANPC1KMT2AALDH1A1HTT | |
| SCHEMBL19002587 | 0.80 | HSD17B1 (0.56) | RAB9ANPC1KMT2A | |
| SCHEMBL3880049 | 0.80 | RAB9A (0.51) | RAB9ANPC1KMT2AMTORALDH1A1 | |
| SCHEMBL3892129 | 0.79 | RAB9A (0.50) | RAB9ANPC1KMT2AALDH1A1HTT | |
| SCHEMBL22012939 | 0.78 | RAB9A (0.49) | RAB9ANPC1KMT2AALDH1A1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170174699-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE | SHY Therapeutics LLC | 2017-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170174699-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE | MAPK6, MAP3K6, MAPK4 | RAB9A 2641/4885NPC1 2024/4885KMT2A 3544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.